Tenax Therapeutics Executive Compensation Details Revealed
Ticker: TENX · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, stock-awards, sec-filing
TL;DR
Tenax Therapeutics DEF 14A out: Executive pay and stock awards for 2022-2024 detailed.
AI Summary
Tenax Therapeutics, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation and stock awards for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on changes in the fair value of outstanding equity awards and vesting dates for awards granted in prior years.
Why It Matters
This filing provides transparency into how Tenax Therapeutics compensates its top executives, which can influence investor decisions and perceptions of company governance.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal information about executive compensation and potential dilution from stock awards that may impact stock price.
Key Players & Entities
- TENAX THERAPEUTICS, INC. (company) — Filer
- 20250425 (date) — Filing Date
- 2022-12-31 (date) — Fiscal Year End
- 2023-12-31 (date) — Fiscal Year End
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing for Tenax Therapeutics, Inc.?
The primary purpose is to provide detailed information regarding the company's executive compensation, including stock awards, for the fiscal years ending December 31, 2022, 2023, and 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What specific types of compensation data are detailed in the filing?
The filing details changes in the fair value of outstanding and unvested equity awards, vesting dates for equity awards, and earnings on equity awards not otherwise reflected in total compensation.
Does the filing mention any former company names for Tenax Therapeutics, Inc.?
Yes, the filing mentions former company names including OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, and SINEQUANON CORP.
What is the business address and phone number for Tenax Therapeutics, Inc. as listed in the filing?
The business address is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517, and the business phone number is 919-855-2100.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding TENAX THERAPEUTICS, INC. (TENX).